Operating profit as a percentage of revenue shrank to 8.9 percent from 20.1 percent
On a Monday morning in early February 2022, Lupin Ltd. found itself at a crossroads familiar to many industrial enterprises navigating a world reshaped by inflation — where growth in revenue and even net profit can coexist with a quietly hollowing core. The pharmaceutical company's operating margins fell by more than half in a single year, revealing how rising input costs can unmask the fragility beneath headline numbers. The market's swift judgment — a 5 percent single-day decline — was less a verdict on Lupin's future than a reckoning with the distance between appearances and underlying health.
- Lupin's operating margin cratered from 20.1% to 8.9% year-over-year, a collapse that no amount of top-line growth could disguise.
- A 24% rise in net profit, celebrated briefly, was quickly exposed as a tax accounting reversal rather than evidence of genuine business strength.
- Raw material costs surged 15%, squeezing every rupee of revenue and leaving the company unable to pass inflation along to its customers.
- Brokerages warned that cost pressures would persist across multiple quarters, keeping the near-term outlook under a heavy cloud.
- Two potential lifelines are taking shape: FDA clearance of a key Goa facility and planned U.S. launches of high-value generics in asthma, cancer, and bowel treatment.
- Analyst opinion remains fractured — 18 buy ratings against 24 hold or sell — reflecting a market still unsure whether Lupin's recovery is a matter of when or if.
Lupin's shares fell more than 5 percent on Monday in their steepest single-day drop in months, after third-quarter results laid bare a troubling divergence between surface-level profit growth and the deteriorating health of the company's core operations.
The central wound was margin compression. Operating profitability shrank from 20.1 percent to just 8.9 percent year-over-year, as a 15 percent surge in expenses — driven by raw material inflation the company could not pass on to customers — consumed the gains from revenue growth. Net profit did rise 24 percent, but analysts quickly noted that the increase owed almost everything to a one-time reversal of deferred tax liabilities, a bookkeeping benefit that obscured rather than resolved the underlying pressure.
Lupin's two largest markets showed genuine momentum — India sales grew 8 percent and U.S. revenue expanded 9 percent — but neither was sufficient to counteract the cost inflation eroding margins across the business. Brokerages signaled that these pressures were unlikely to ease quickly, casting a shadow over the next several quarters.
Still, analysts identified reasons for longer-term optimism. The U.S. Food and Drug Administration cleared a key manufacturing facility in Goa, lifting a regulatory constraint that had limited product supply. And Lupin is preparing to launch generic versions of high-value drugs — targeting asthma, cancer, and bowel preparation — in the U.S. market, moves that could meaningfully lift revenue in the second half of fiscal year 2023.
Of 42 analysts tracking the stock, 18 recommended buying while 24 advised holding or selling — a split that captured the market's uncertainty. The consensus price target implied modest upside of roughly 9.6 percent, a figure that reflected not confidence in a swift recovery, but a cautious wager that Lupin's structural advantages might eventually outlast its present cost crisis.
Lupin's stock price dropped sharply on Monday morning, falling more than 5 percent in its steepest single-day decline since late November. The sell-off came after the pharmaceutical company reported third-quarter results that exposed a widening gap between what investors had expected and what the numbers actually showed.
The core problem was simple and brutal: margins had collapsed. Operating profit as a percentage of revenue shrank to 8.9 percent from 20.1 percent a year earlier—a loss of more than half the company's profitability cushion. The culprit was a 15 percent jump in expenses, driven largely by surging raw material costs that the company could not fully pass along to customers. Even though the company's net profit technically rose 24 percent, that gain was almost entirely due to a one-time reversal of deferred tax liabilities, a bookkeeping benefit that masked the underlying deterioration in the business.
The numbers revealed a company caught between competing pressures. In India, Lupin's home market, sales grew a respectable 8 percent year-over-year. The U.S. business, which accounts for the bulk of the company's revenue and profit, managed 9 percent growth. On the surface, these figures looked healthy. But they were not enough to offset the cost inflation eating into every rupee of sales.
Wall Street's reaction was swift. Brokerages that follow the company signaled they expected these cost pressures to persist in the near term, weighing on profitability across the next several quarters. The immediate outlook was grim. Yet analysts were not entirely pessimistic about the longer term. They pointed to two potential catalysts that could help Lupin recover lost ground in the second half of the next financial year: the company planned to launch generic versions of several high-value drugs—treatments for asthma, cancer, and bowel preparation—in the U.S. market. Additionally, the U.S. Food and Drug Administration had cleared a key manufacturing facility in Goa, removing a regulatory overhang that had constrained the company's ability to supply certain products.
The analyst community remained divided on the stock's prospects. Of the 42 analysts tracking Lupin, 18 rated it a buy, while 12 each recommended holding or selling. The consensus price target suggested the stock could rise 9.6 percent from current levels—a modest upside that reflected the uncertainty about when, or even whether, the company could restore its margins to historical levels. For now, investors were punishing the stock for the present pain, betting that the company's cost structure would remain under pressure until new product launches and manufacturing improvements could shift the equation.
Notable Quotes
Brokerages expect inflationary pressures to continue to weigh on the company's profitability in the near term— Analyst consensus
The Hearth Conversation Another angle on the story
Why did the stock fall so hard if the company is still growing sales in both its major markets?
Because growth doesn't matter if you're losing money on every unit you sell. The margins collapsed—that's what investors care about. You can grow 9 percent and still be in trouble if your costs are growing faster.
But the net profit went up 24 percent. Isn't that good news?
That's the trap. Almost all of that gain came from a tax accounting reversal, not from the business actually performing better. Strip that out and the underlying profit was down sharply.
So what's the path back? Can they fix this?
That's what the brokerages are betting on. New generic drug launches in the U.S. next year, plus FDA clearance for a facility that's been held up. Those could drive volume and help spread costs across more sales.
How long do they have to wait?
That's the real question. The consensus is that cost pressures will linger in the near term. So we're talking quarters, not months. Investors are impatient.
What do the analysts actually think?
Mixed. Eighteen buy, twelve hold, twelve sell. The price target suggests modest upside, maybe 10 percent. Nobody's excited. They're waiting to see if the company can execute on those launches and actually restore margins.